121 related articles for article (PubMed ID: 18261151)
1. Cryoablative response of prostate cancer cells is influenced by androgen receptor expression.
Klossner DP; Baust JM; VanBuskirk RG; Gage AA; Baust JG
BJU Int; 2008 May; 101(10):1310-6. PubMed ID: 18261151
[TBL] [Abstract][Full Text] [Related]
2. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
3. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
4. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
5. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
Song Y; Wu G; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
7. Improvement in predicting tumorigenic phenotype of androgen-insensitive human LNCaP prostatic cancer cell subline in recombination with rat urogenital sinus mesenchyme.
Kanai M; Ishii K; Kanda H; Ogura Y; Kise H; Arima K; Sugimura Y
Cancer Sci; 2008 Dec; 99(12):2435-43. PubMed ID: 19018772
[TBL] [Abstract][Full Text] [Related]
8. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
[TBL] [Abstract][Full Text] [Related]
9. Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
Takahara K; Azuma H; Sakamoto T; Kiyama S; Inamoto T; Ibuki N; Nishida T; Nomi H; Ubai T; Segawa N; Katsuoka Y
Anticancer Res; 2009 Jul; 29(7):2497-505. PubMed ID: 19596919
[TBL] [Abstract][Full Text] [Related]
10. Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer.
Clarke DM; Robilotto AT; VanBuskirk RG; Baust JG; Gage AA; Baust JM
Prostate Cancer Prostatic Dis; 2007; 10(2):175-84. PubMed ID: 17297503
[TBL] [Abstract][Full Text] [Related]
11. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
12. Cryosurgical technique: assessment of the fundamental variables using human prostate cancer model systems.
Klossner DP; Robilotto AT; Clarke DM; VanBuskirk RG; Baust JM; Gage AA; Baust JG
Cryobiology; 2007 Dec; 55(3):189-99. PubMed ID: 17888898
[TBL] [Abstract][Full Text] [Related]
13. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells.
Mehraein-Ghomi F; Lee E; Church DR; Thompson TA; Basu HS; Wilding G
Prostate; 2008 Jun; 68(9):924-34. PubMed ID: 18386285
[TBL] [Abstract][Full Text] [Related]
14. Emodin induces apoptosis in human prostate cancer cell LNCaP.
Yu CX; Zhang XQ; Kang LD; Zhang PJ; Chen WW; Liu WW; Liu QW; Zhang JY
Asian J Androl; 2008 Jul; 10(4):625-34. PubMed ID: 18478162
[TBL] [Abstract][Full Text] [Related]
15. E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis.
Libertini SJ; Tepper CG; Guadalupe M; Lu Y; Asmuth DM; Mudryj M
Prostate; 2006 Jan; 66(1):70-81. PubMed ID: 16114066
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells.
Zaidman BZ; Wasser SP; Nevo E; Mahajna J
Int J Oncol; 2007 Oct; 31(4):959-67. PubMed ID: 17786330
[TBL] [Abstract][Full Text] [Related]
17. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor and invasion in prostate cancer.
Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
[TBL] [Abstract][Full Text] [Related]
19. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
20. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
